Handelsbanken Fonder AB Acquires 4,000 Shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)

Handelsbanken Fonder AB increased its stake in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 9.9% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 44,400 shares of the biopharmaceutical company’s stock after buying an additional 4,000 shares during the period. Handelsbanken Fonder AB’s holdings in Alexion Pharmaceuticals were worth $5,402,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. BlackRock Inc. raised its position in shares of Alexion Pharmaceuticals by 2,689.8% in the first quarter. BlackRock Inc. now owns 18,628,080 shares of the biopharmaceutical company’s stock valued at $2,258,467,000 after buying an additional 17,960,356 shares during the period. Jennison Associates LLC raised its position in shares of Alexion Pharmaceuticals by 15.8% in the first quarter. Jennison Associates LLC now owns 9,622,914 shares of the biopharmaceutical company’s stock valued at $1,166,682,000 after buying an additional 1,309,529 shares during the period. State Street Corp raised its position in shares of Alexion Pharmaceuticals by 6.8% in the first quarter. State Street Corp now owns 11,298,685 shares of the biopharmaceutical company’s stock valued at $1,369,846,000 after buying an additional 718,756 shares during the period. Marshall Wace North America L.P. bought a new position in shares of Alexion Pharmaceuticals during the first quarter valued at approximately $65,219,000. Finally, Ameriprise Financial Inc. raised its position in shares of Alexion Pharmaceuticals by 8.0% in the first quarter. Ameriprise Financial Inc. now owns 6,149,572 shares of the biopharmaceutical company’s stock valued at $745,579,000 after buying an additional 454,069 shares during the period. 94.14% of the stock is owned by hedge funds and other institutional investors.

Alexion Pharmaceuticals, Inc. (ALXN) opened at 123.06 on Monday. The stock has a 50 day moving average of $112.16 and a 200 day moving average of $122.31. The stock has a market capitalization of $27.63 billion, a P/E ratio of 58.63 and a beta of 1.39. Alexion Pharmaceuticals, Inc. has a 52 week low of $96.18 and a 52 week high of $145.41.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings data on Thursday, April 27th. The biopharmaceutical company reported $1.38 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.05 by $0.33. The business had revenue of $870 million for the quarter, compared to the consensus estimate of $826.63 million. Alexion Pharmaceuticals had a net margin of 14.52% and a return on equity of 11.72%. Alexion Pharmaceuticals’s quarterly revenue was up 24.3% on a year-over-year basis. During the same quarter last year, the company posted $1.11 earnings per share. On average, equities research analysts predict that Alexion Pharmaceuticals, Inc. will post $5.31 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This story was originally posted by WKRB News and is the sole property of of WKRB News. If you are accessing this story on another domain, it was illegally copied and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be read at https://www.wkrb13.com/markets/2285220/handelsbanken-fonder-ab-acquires-4000-shares-of-alexion-pharmaceuticals-inc-nasdaqalxn.html.

ALXN has been the subject of several research analyst reports. Leerink Swann set a $208.00 price target on shares of Alexion Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, March 13th. Morgan Stanley raised shares of Alexion Pharmaceuticals from an “equal weight” rating to an “overweight” rating and upped their price target for the stock from $101.08 to $138.00 in a research report on Thursday, May 25th. Barclays PLC reaffirmed an “overweight” rating and set a $155.00 price target on shares of Alexion Pharmaceuticals in a research report on Tuesday, May 9th. Cowen and Company reaffirmed an “outperform” rating and set a $180.00 price target on shares of Alexion Pharmaceuticals in a research report on Friday, April 28th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $177.00 price target on shares of Alexion Pharmaceuticals in a research report on Monday, March 27th. Eight analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $158.74.

In other Alexion Pharmaceuticals news, Director Bros. Advisors Lp Baker purchased 1,348,955 shares of the firm’s stock in a transaction on Wednesday, June 14th. The shares were purchased at an average price of $116.32 per share, for a total transaction of $156,910,445.60. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Ludwig Hantson purchased 10,000 shares of the firm’s stock in a transaction on Wednesday, June 14th. The shares were acquired at an average price of $116.72 per share, for a total transaction of $1,167,200.00. Following the purchase, the chief executive officer now directly owns 38,725 shares of the company’s stock, valued at $4,519,982. The disclosure for this purchase can be found here. In the last 90 days, insiders bought 2,019,734 shares of company stock worth $235,606,846. 4.35% of the stock is currently owned by corporate insiders.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2285220/handelsbanken-fonder-ab-acquires-4000-shares-of-alexion-pharmaceuticals-inc-nasdaqalxn.html

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

 


Leave a Reply

 
© 2006-2017 WKRB News.